Membrane phospholipid abnormalities of basal ganglia in never-treated schizophrenia: A 31P magnetic resonance spectroscopy study

Biological Psychiatry

Volumn 54, Issue 4, 2003, Pages 491-494

  Jayakumar, Perumbava N ^a   Gangadhar, Bangalore N ^a   Subbakrishna, Doddaballapur K ^a   Janakiramaiah, Nimmagadda ^a   Srinivas, Jakka S ^a   Keshavan, Matcheri S ^b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Basal ganglia; Magnetic resonance spectroscopy; Membrane phospholipids; Phosphodiester; Phosphomonoester; Schizophrenia

Indexed keywords

ESTER DERIVATIVE; MEMBRANE PHOSPHOLIPID;

ADULT; ARTICLE; BASAL GANGLION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IN VIVO STUDY; MALE; NEGATIVE SYNDROME; NERVE CELL DIFFERENTIATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHOLIPID MEMBRANE; POSITIVE SYNDROME; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA;

EID: 0142011199     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01829-2     Document Type: Article

References (23)

1. Diagnostic and Statistical Manual. 4th edition :1994;American Psychiatric Press, Washington, DC.
2. Bottomley P.A. Spatial localization in NMR spectroscopy in vivo. Ann N Y Acad Sci. 508:1987;333-348.
3. Bovee WMMJ, de Beer R, Ormondt DV, et al (2000): Quantitation in In vivo MRS. In: Ian R. Young, editor. Methods in Biomedical Magnetic Resonance Imaging and Spectroscopy. New York: John Wiley & Sons, Ltd., 803-810.
4. Deicken R.F., Calabrese G., Merrin E.L., Meyerhoff D.J., Dillon W.P., Weiner M.W., et al. 31 Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. Biol Psychiatry. 36:1994;503-510.
5. Frahm J, Hanicke W (2000): Single Voxel localized proton NMR Spectroscopy of human brain in vivo. In: Ian R. Young, editor. Methods in Biomedical Magnetic Resonance Imaging and Spectroscopy. New York: John Wiley & Sons, Ltd., 735-751.
6. Fujimoto T., Nakano T., Takano T., Hokazono Y., Asakura T., Tsuji T., et al. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging. Acta Psychiatr Scand. 86:1992;455-462.
7. Goldman P.S., Galkin T.W. Prenatal removal of frontal association cortex in the fetal rhesus monkey Anatomical and functional consequences in postnatal life . Brain Res. 152:1978;451-485.
8. Kato T., Shioiri T., Murashita J., Hamakawa H., Inubushi T., Takahashi S. Lateralised abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorous-31 magnetic resonance spectroscopy of frontal lobes in schizophrenia. Psychiatry Res. 61:1995;151-160.
9. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS) Rationale and standardization . Br J Psychiatry Suppl. 7:1989;59-67.
10. Keshavan M.S., Bagwell W.W., Haas G.L., Sweeney J.A., Schooler N.R., Pettegrew J.W., et al. Changes in caudate volume with neuroleptic treatment. Lancet. 344:1994;1434.
11. Keshavan M.S., Stanley J.A., Pettegrew J.W. Magnetic resonance spectroscopy in schizophrenia Methodological issues and findings - part II . Biol Psychiatry. 48:2000;369-380.
12. Lauer M., Beckmann H. The human striatum in schizophrenia. 1. Increase in overall relative striatal volume in schizophrenics. Psychiatry Res. 68:1997;87-98.
13. Murray R.M., Lewis S.W. Is schizophrenia a neurodevelopmental disorder? Br Med J. 295:1987;681-682.
14. Pettegrew J.W., Keshavan M.S., Panchalingam K., Strychor S., Kaplan D.B., Tretta M.G., et al. Alterations of brain high-energy phosphate and membrane phospholipid metabolism in first episode drug naive schizophrenics. Arch Gen Psychiatry. 48:1991;563-568.
15. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Harvey P.D., Newman A., et al. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Arch Gen Psychiatry. 55:1998;235-243.
16. Shioiri T., Kato T., Inubushi T., Murashita J., Takahashi S. Correlations of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Schizophr Res. 55:1994;223-235.
17. Stanley J.A., Pettegrew J.W. Postprocessing method to segregate and quantify the broad components underlying the phosphodiester spectral region of in vivo 31P brain spectra. Magn Reson Med. 45:2001;390-396.
18. Stanley T.A., Pettegrew J.W., Keshavan M.S. Magnetic resonance spectroscopy in schizophrenia Methodological issues and findings - part I . Biol Psychiatry. 48:2000;357-368.
19. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Malla A., et al. Membrane phospholipid metabolism and schizophrenia An in vivo 31P-MR spectroscopy study . Schizophr Res. 13:1994;209-215.
20. Stanley J.A., Williamson P.C., Drost D.J., Carr T.J., Rylett R.J., Malla A., et al. An in vivo study of the prefrontal cortex of schizophrenia patients at different stages of illness via phosphorus magnetic resonance spectroscopy. Arch Gen Psychiatry. 53:1996;1065-1066.
21. Volz H.R., Riehemann S., Maurer I., Smesny S., Sommer M., Rzanny R., et al. Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients A (31)P chemical shift spectroscopic-imaging study . Biol Psychiatry. 47:2000;954-961.
22. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 44:1987;660-669.
23. Williamson P., Drost D., Stanley J., Carr T., Morrison S., Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal control subjects. Arch Gen Psychiatry. 48:1991;578. [letter].